Medigen to publish COVID-19 analysis on U.S. journal – Focus Taiwan

Taipei, Feb. 2 (CNA) A COVID-19 vaccine analysis from Taiwan-based Medigen Vaccine Biologics Corp., which discovered its locally-produced vaccine was as efficient because the Moderna and Pfizer BioNTech vaccines, will probably be featured in a United States medical publication.

The analysis paper will probably be printed within the March subject of Rising Infectious Ailments, a month-to-month peer-reviewed journal from the U.S. Facilities for Illness Management and Prevention, Taiwan’s Facilities for Illness Management (CDC) Deputy Director Common Lo Yi-chun (羅一鈞) instructed CNA on Friday.

Lo stated Medigen will probably be publishing the constructive outcomes of its protein subunit COVID-19 vaccine, which has been confirmed to offer 90 p.c safety in opposition to reasonable to extreme infections on people who get three jabs.

The protein subunit vaccine is efficient in opposition to the Omicron subvariant, and will defend these receiving the inoculation from reasonable to extreme signs and even dying, in accordance with Lo.

Furthermore, Medigen’s analysis paperwork are the primary large knowledge comparability between the strengths of mRNA and protein subunit vaccines, he added.

Taiwan’s CDC defined that knowledge for the analysis have been collected domestically in Taiwan by means of the nation’s vaccine rollout packages.

The information used for the comparability was primarily based on greater than 60 million vaccine jabs acquired by over 23 million people in the course of the mass Omicron group infections that broke out domestically in 2022.

The CDC stated the analysis concluded that Medigen’s protein subunit inoculation supplied safety in opposition to COVID-19 that’s akin to that supplied by the vaccines developed by Moderna and Pfizer BioNTech, which have been confirmed to be extra environment friendly and lengthy lasting than these from Astrazeneca (AZ).

The analysis fully maps out the energy of varied vaccine mixtures between completely different age teams and the outcomes can be found to consultants world wide, the CDC stated.

Lo instructed CNA that Medigen’s findings have already been made public and offered on the thirtieth Convention on Retroviruses and Opportunistic Infections in Seattle final February.

The CDC additionally suggested anybody who acquired an AZ vaccine as their first two preliminary inoculation jabs to get further boosters with next-generation serums.